Literature DB >> 23499398

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.

Doraid Alrifai1, Sanjay Popat, Merina Ahmed, David Gonzalez, Andrew G Nicholson, John du Parcq, Tim Benepal.   

Abstract

The management of non-small cell lung cancer has significantly changed over the past few years through greater understanding of tumour biology. The identification of activating mutations has led to the development of targeted agents. Coexisting mutations in non-small cell lung cancer is uncommon, particularly in squamous cell carcinoma. Our case represents a late gentleman with squamous cell carcinoma of the lung with both a BRAF mutation and ALK rearrangement prior to treatment. Crown
Copyright © 2013. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23499398     DOI: 10.1016/j.lungcan.2013.02.002

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Authors:  Liza C Villaruz; Mark A Socinski; Shira Abberbock; Lynne D Berry; Bruce E Johnson; David J Kwiatkowski; A John Iafrate; Marileila Varella-Garcia; Wilbur A Franklin; D Ross Camidge; Lecia V Sequist; Eric B Haura; Mark Ladanyi; Brenda F Kurland; Kelly Kugler; John D Minna; Paul A Bunn; Mark G Kris
Journal:  Cancer       Date:  2014-10-01       Impact factor: 6.860

2.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Authors:  Daniel Morgensztern; Meghan J Campo; Suzanne E Dahlberg; Robert C Doebele; Edward Garon; David E Gerber; Sarah B Goldberg; Peter S Hammerman; Rebecca S Heist; Thomas Hensing; Leora Horn; Suresh S Ramalingam; Charles M Rudin; Ravi Salgia; Lecia V Sequist; Alice T Shaw; George R Simon; Neeta Somaiah; David R Spigel; John Wrangle; David Johnson; Roy S Herbst; Paul Bunn; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

3.  ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Authors:  Dara L Aisner; Teresa T Nguyen; Diego D Paskulin; Anh T Le; Jerry Haney; Nathan Schulte; Fiona Chionh; Jenny Hardingham; John Mariadason; Niall Tebbutt; Robert C Doebele; Andrew J Weickhardt; Marileila Varella-Garcia
Journal:  Mol Cancer Res       Date:  2013-12-02       Impact factor: 5.852

4.  Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry.

Authors:  Jiandong Wang; Qin Shen; Qunli Shi; Bo Yu; Xuan Wang; Kai Cheng; Guangming Lu; Xiaojun Zhou
Journal:  J Exp Clin Cancer Res       Date:  2014-12-21

5.  ALK-rearranged squamous cell carcinoma of the lung.

Authors:  Yusuke Takanashi; Shogo Tajima; Shun Matsuura; Shin Koyama; Tsuyoshi Takahashi; Hiroshi Neyatani
Journal:  Respirol Case Rep       Date:  2015-07-02

Review 6.  ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

Review 7.  [Treatment of Advanced Squamous Cell Lung Cancer].

Authors:  Yixiang Zhu; Puyuan Xing; Junling Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-10-20

8.  Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

Authors:  Junko Watanabe; Shinsaku Togo; Issei Sumiyoshi; Yukiko Namba; Kentaro Suina; Takafumi Mizuno; Kotaro Kadoya; Hiroaki Motomura; Moe Iwai; Tetsutaro Nagaoka; Shinichi Sasaki; Takuo Hayashi; Toshimasa Uekusa; Kanae Abe; Yasuo Urata; Fuminori Sakurai; Hiroyuki Mizuguchi; Shunsuke Kato; Kazuhisa Takahashi
Journal:  Oncotarget       Date:  2018-05-08

9.  ALK-rearranged squamous cell carcinoma of the lung.

Authors:  Qiyi Meng; Yujie Dong; Hong Tao; Liang Shi; Li Tong; Junfang Tang; Shucai Zhang; Zhe Liu
Journal:  Thorac Cancer       Date:  2021-02-09       Impact factor: 3.500

10.  Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.

Authors:  Weihong Guo; Jianping Liang; Dandan Zhang; Xikun Huang; Yanhua Lv
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.